AI Summary
Addex Therapeutics reported Q1 2026 results with a net loss of CHF 1.71 million and cash of CHF 0.94 million. The company highlighted Neurosterix progress toward completing the NTX-253 Phase 1 study in July, which could serve as a near-term catalyst, while cash burn persists and GABAB/M4 programs advance in preclinical stages.
Sentiment Rationale
The results show a cash burn and losses, which may pressure the stock; however, a near-term data catalyst for NTX-253 in July could generate upside if data are favorable. Market reaction will hinge on the data readout and cash runway.
Trading Thesis
NTX-253 July Phase 1 data could drive near-term upside; expect price volatility around the catalyst.
Market-Moving
- NTX-253 Phase 1 data due in July could drive ADXN volatility.
- Cash on hand ~CHF 0.94m raises dilution and financing risk.
- Neurosterix spin-out progress may unlock value in the long run.
Key Facts
- Q1 2026 net loss CHF 1.71m. Cash and equivalents CHF 0.94m.
- NTX-253 Phase 1 data due July 2026. Neurosterix progress on track.
- GABAB PAM chronic cough preclinical; Spin-out 20% Neurosterix stake.
- R&D near nil; operating loss CHF -0.48m; cash burn persists.
- Conference call June 25, 2026; data-driven updates potential catalyst.
Companies Mentioned
- Addex Therapeutics (ADXN): Primary company; Q1 results and NTX-253 Phase 1 July data.
- Neurosterix US Holdings LLC: Spin-out; 20% stake; NTX-253 development progress.
- Indivior PLC (INVR): Partner; potential impact on GABAB/M4 programs; not a direct equity move.
- Stalicla: Private investor; strategic tie; unlikely near-term price impact.
Earnings
Category: Earnings and Corporate Developments; ADXN provides quarterly results and pipeline updates, including spin-out progress and catalyst timing, aligning with earnings/biopharma corporate coverage.